Letrozole, alias femara, is a white or off-white powder of chemicals. It is a new generation of aromatase inhibitor, which is a synthetic benzyltriazole derivative. Letrozole can reduce the estrogen level by inhibiting aromatase, thereby eliminating the stimulating effect of estrogen on tumor growth. Endocrine therapy for breast cancer.Femara powder
In vitro and in vivo studies have shown that letrozole can effectively inhibit the conversion of androgen to estrogen, while estrogen in postmenopausal women is mainly derived from the aromatization of androgen precursors in peripheral tissues, so it is especially suitable for postmenopausal breast cancer. patient. Letrozole is 150-250 times more potent than the first-generation aromatase inhibitor, aminoglutethimide. Because of its high selectivity, it does not affect glucocorticoids, mineralocorticoids and thyroid function. High doses have no inhibitory effect on the secretion of adrenocortical steroids and therefore have a higher therapeutic index. Various preclinical studies have shown that letrozole has no potential toxicity to various systems and target organs, and has the characteristics of good tolerance and strong pharmacological action. Letrozole has a stronger antitumor effect than other aromatase inhibitors and antiestrogens
There is no clinical correlation between gender, age, and liver and kidney function and letrozole, so elderly patients and patients with impaired liver and kidney function do not have to adjust the dose. According to years of clinical experience, it also has ovulation-promoting effect.